Trial Profile
A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cinrebafusp alfa (Primary)
- Indications Advanced breast cancer; Bladder cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Pieris Pharmaceuticals
- 19 Apr 2024 Status changed from active, no longer recruiting to completed.
- 29 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 28 Jan 2021 Planned End Date changed from 1 Feb 2021 to 1 Jul 2021.